Life Sciences 360

Life Sciences 360 is an interview show that educates anyone on challenges, trends, and insights in the life-sciences industry. Hosted by Harsh Thakkar, a life-sciences industry veteran and CEO and co-founder of Qualtivate, the show features subject-matter experts, business leaders, and key life-science partners contributing to bringing new therapies to patients worldwide. Harsh is passionate about advancements in life sciences and tech and is always eager to learn from his guests— making the show both informative and useful.

Life Sciences 360 is a science podcast hosted by Harsh Thakkar, with 86 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Harsh Thakkar hosts Life Sciences 360, a science show with 86 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #86

  Why Every Medical Affairs Team Needs Their Own AI Agent in 2025

  Aug 6, 202549 minS4

  <p>Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator). <br/><br/>Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing.<br/><br/>⚡️ WHAT YOU’LL LEARN:<br/><br/>- Why medical affairs and regulatory teams can’t rely on ChatGPT alone.<br/><br/>- How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing <br/><br/>- Why MACg users report u...

  ListenShow Notes
• 

  Episode #85

  VC Money Tight? Here’s How Startups Still Land Top Talent (2025)

  Jul 17, 202547 minS4

  <p>What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds? <br/><br/>Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams.<br/><br/>In this episode you’ll learn:<br/><br/>- Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators. <br/><br/>- The three traits VCs demand in first-time biotech CEOs during a funding slump. <br/><br/>- How AI-driven platforms like Isomorphic Labs raised mega-rounds...

  ListenShow Notes
• 

  Episode #84

  Why Most Healthcare Brands Fail (And How to Fix It)

  May 28, 202551 minS3

  <p>Why Most Healthcare Brands Fail (And How to Fix It)<br/><br/>In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling.<br/><br/>You’ll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with pati...

  ListenShow Notes
• 

  Episode #83

  4.5 Billion Molecules, One Mission: Cure the ‘Undruggable’ Diseases

  May 14, 202531 minS3

  <p>Solving the “Undruggable” Disease Problem with Goldilocks Molecules<br/><br/>In this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer’s, certain cancers, and rare genetic disorders.<br/><br/>Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces.<br/><br/>We al...

  ListenShow Notes
• 

  Episode #82

  What Separates Life Science Startup Winners from Losers?

  Apr 30, 202539 minS3

  <p>Why Startups Fail (Hint: It’s Not the Innovation)<br/><br/>In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science.<br/><br/>Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that actually scales. You’ll also learn why execution beats experimentation when commercial success is the goal—and how to stay...

  ListenShow Notes

Recent guests on Life Sciences 360. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.